In a move that underlines continuity at Valiant Laboratories Limited, the board approved a slate of leadership decisions at its August 10, 2026 meeting. Central to the mix is the re-appointment of Santosh Vora as Managing Director for a five-year term beginning February 6, 2027, with remuneration details to be finalized following the company’s forthcoming AGM. The decision signals confidence in the executive leadership steering the company’s chemistry-driven growth path.
The board also re-appointed Sonal Vira as an Independent Director for a second five-year term, effective February 16, 2027. Her confirmation underscores a commitment to independent oversight and governance, with assurances that she meets the independence criteria laid out under applicable corporate law and listing requirements.
Additionally, the board approved the continuation of Shantilal Vora as a Non-Executive Non-Independent Director from November 5, 2027, when he will have reached the age of 75, subject to shareholder approval at the AGM. This decision preserves continuity and the depth of institutional knowledge on the board as the company advances its strategic agenda.
Beyond governance, the announcements touch on broader corporate moves, including the company’s plan to open a new corporate office and pursue strategic investments in its wholly owned subsidiary VASPL, reflecting an integrated approach to strengthening operational footprint and financial backbone while maintaining leadership consistency at the top.